文献速递淋巴瘤

套细胞淋巴瘤中LRPAP1自身抗体与更优结局相关

LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome.
PubMed 文献 · Blood · 2021-01-01

在欧洲MCL网络Younger和Elderly试验治疗的312例可评估MCL患者中,41例(13%)检出LRPAP1自身抗体,以IgG类且轻链限制性为主。该抗体存在与基线临床特征无关,但与更优的5年FFS和OS显著相关,校正MIPI后风险比仍支持更优结局。

要点

  • MCL患者中LRPAP1自身抗体检出率为13%(41/312)。
  • 抗体阳性者5年FFS为70% vs 51%,OS为93% vs 68%。
  • 校正MIPI后FFS的HR为0.48,OS的HR为0.47。

核心结论

  • LRPAP1自身抗体在大型前瞻性多中心临床试验治疗的MCL患者中频繁检出,且提示更优结局。

研究设计与样本

  • 分析欧洲MCL网络Younger和Elderly试验中312例可评估MCL患者的血清LRPAP1自身抗体,检测其频率、与疾病特征关联及预后影响。

主要发现

  • 41例(13%)检出LRPAP1自身抗体,以IgG类为主且克隆性轻链限制(27例κ轻链,14例λ轻链),滴度范围1:400至1:3200。
  • 抗体存在与任何基线临床特征均无显著关联。

临床怎么用

  • LRPAP1自身抗体检测或可辅助MCL预后分层,抗体阳性提示更优FFS和OS。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Low-density lipoprotein (LDL) receptor-related protein-associated protein 1 (LRPAP1) had been identified by B-cell receptor (BCR) expression cloning and subsequent protein array screening as a frequent and proliferation-inducing autoantigen of mantle cell lymphoma (MCL). Of interest, high-titered and light chain-restricted LRPAP1 autoantibodies were detected in 8 of 28 patients with MCL. In the present study, LRPAP1 autoantibodies in sera of patients treated within the Younger and Elderly trials of the European MCL Network were analyzed regarding frequency, association with disease characteristics, and prognostic impact. LRPAP1 autoantibodies were detected in 41 (13%) of 312 evaluable patients with MCL. These LRPAP1 autoantibodies belonged predominantly to the immunoglobulin G (IgG) class and were clonally light chain restricted (27 with κ light chains, 14 patients with λ light chains). Titers ranged between 1:400 and 1:3200. The presence of LRPAP1 autoantibodies was not significantly associated with any baseline clinical characteristic, however, it was associated with a superior 5-year probability for failure-free survival (FFS) of 70% (95% confidence interval [CI], 57% to 87%) vs 51% (95% CI, 44% to 58%), P = .0052; and for overall survival (OS) of 93% (95% CI, 85% to 100%) vs 68% (95% CI, 62% to 74%), P = .0142. LRPAP1-seropositive patients had a Mantle Cell Lymphoma International Prognostic Index-adjusted hazard ratio for FFS of 0.48 (95% CI 0.27-0.83, P = .0083) and for OS of 0.47 (95% CI 0.24-0.94, P = .032). LRPAP1 autoantibodies were frequently detected in a large cohort of MCL patients treated within prospective multicenter clinical trials. Our results suggest better outcomes for LRPAP1-autoantibody seropositive patients.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Thurner L, Fadle N, Bittenbring JT, et al. LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome. Blood. 2021. PMID: 33513604. doi:10.1182/blood.2020008835

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。